"Medical uses of pharmaceutical delta-9-Tetrahydrocannabinol (such as Marinol) for the treatment of illnesses associated with wasting, such as AIDS, the treatment of emesis associated with chemotherapy, or for other indications should be carefully controlled.

If smoked marijuana should be approved for medical use based on scientific evidence, through the normal regulatory process that applies to all scheduled drugs, its administration should be only under the supervision of a knowledgeable physician.

Research on marijuana, including both basic science and applied clinical studies, should receive increased funding and appropriate access to marijuana for study. The mechanisms of action of marijuana, its effect on the human body, its addictive properties, and any appropriate medical applications should be investigated, and the results made known for clinical and policy applications. In addition, ASAM strongly encourages research related to the potential and actual effects of marijuana-related public policy.

ASAM encourages the study of the potential impact of making cannabis available for approved medical uses, and the consideration of what changes might result from moving cannabis from Schedule I to another Schedule.

• "Increase access to and improve the quality of addictions treatment.
• Educate physicians, medical and osteopathic students, and the public.
• Promoting research and prevention.
• Establish addiction medicine as a specialty recognized by the American Board of Medical Specialties."

Publishes Journal of Addictive Diseases